Since the LEAD program’s inception in 2008, CSL Behring has awarded more than $250,000 in three semi-annual grant cycles.
"CSL Behring is dedicated to advocacy and is honored to be able to collaborate with patient advocacy organizations to improve access to life-saving plasma-derived and recombinant therapies," said Dennis Jackman, CSL Behring Senior Vice President, Public Affairs. "CSL Behring is committed to helping organizations expand their advocacy initiatives and capabilities on both the state and federal levels."
In this most recent round of awards two Chicago-based patient organizations were selected to receive grants, from among the 19 submissions received. LEAD grants were awarded to:
- The Respiratory Health Association of Metropolitan Chicago, which promotes healthy lungs and fights lung disease through research, advocacy, and education, will use its funding for advocacy and education. It will advocate for legislation mandating that the Illinois Department of Health assign a staff member exclusively to COPD/Alpha-1 antitrypsin deficiency. It will also advocate for the creation of a $250,000 line item in the Illinois state budget to develop a statewide education, awareness and surveillance plan for COPD/Alpha-1 antitrypsin deficiency.
- The Hemophilia Foundation of Illinois, a state chapter of the National Hemophilia Foundation (NHF) dedicated to the treatment of all bleeding and clotting disorders, will use its grant to fund advocacy efforts depleted by a $700,000 reduction in the state hemophilia program. The Foundation also plans to create a public health program guide for Illinois residents with bleeding disorders.
No comments:
Post a Comment